Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies Eucure and Syncromune Establish Technology Transfer Agreement for YH002...
Category: News
Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Combination Immunotherapy Platform
Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active...
Syncromune, Inc. to Present at 2022 BIO CEO & Investor Conference
Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference FORT...